Download PDF
Exp Clin Endocrinol Diabetes 2008; 116(2): 86-93
DOI: 10.1055/s-2007-985382
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Metabolic Characteristics of Glucose Intolerance: The Critical Role of Obesity

P. P. Sainaghi 1 , L. Castello 1 , L. Bergamasco 1 , G. P. Carnevale Schianca 1 , E. Bartoli 1
  • 1Internal Medicine, Dipartimento di Medicina Clinica e Sperimentale, Università del Piemonte Orientale “A. Avogadro”, Novara, Italy
Further Information

Publication History

received 29.01.2007 first decision 23.05.2007

accepted 17.07.2007

Publication Date:
31 October 2007 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction: Obesity enhances insulin secretion and resistance. We investigated its importance in linking insulin metabolism to glucose intolerance.

Material and Methods: We studied 700 subjects referred by general practitioners for possible metabolic abnormalities. Plasma glucose was measured before (FPG) and after (2h-PG) OGTT, together with insulin. Insulin resistance was estimated by HOMA-IR, insulin sensitivity using ISI(gly) and ISI(Stumvoll) indexes, insulin secretion by first (1stPHest) and second phase (2ndPHest) estimates.

Results: Sixty three subjects had impaired glucose tolerance (IGT), 132 impaired fasting glucose (IFG), 63 a mixed disorder (IFG/IGT). Insulin resistance was present only in IGT and IFG/IGT. IFG sub-jects had inappropriately low insulin secretionexclusively during fasting. In a stepwise logistic regression analysis BMI≥27, female sex and hy-pertension were associated to an altered 2h-PG during OGTT, while hypertension and age were linked to alterations in FPG. While overweight prevalence (BMI≥27) was higher in all glucose intolerance groups, obesity (BMI≥30) was typical of IGT. Overweight and obesity were related to higher insulin concentration, secretion and resistance. Obese normal glucose tolerant subjects were more insulin resistant than lean IFG patients.

Discussion: OGTT is essential to correctly establish the metabolic derangement of glucose intolerance. Obesity is significantly connected with the impairment of insulin metabolism even in subjects with normal FPG. Considering that both obesity and insulin resistance are independently associated to an increased cardiovascular risk, all overweight subjects, even with normal FPG, should be referred for OGTT evaluation to define glucose tolerance status in order to enforce adequate preventive actions.

Key words

glucose intolerance - IGT - IFG - obesity - BMI - insulin

References

  • 1 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.  Diabet Med. 1998;  15 539-553
    CrossrefPubMedGoogle Scholar
  • 2 American Diabetes Association . Diagnosis and classification of diabetes mellitus.  Diabetes Care. 2005;  28 S37-S42
    CrossrefPubMedGoogle Scholar
  • 3 Belfiore F, Iannello S, Volpicelli G. Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels.  Mol Genet Metab. 1998;  63 134-141
    CrossrefPubMedGoogle Scholar
  • 4 Carnevale Schianca GP, Rossi A, Sainaghi PP, Maduli E, Bartoli E. The significance of impaired fasting glucose versus impaired glucose tolerance: importance of insulin secretion and resistance.  Diabetes Care. 2003;  26 1333-1337
    CrossrefPubMedGoogle Scholar
  • 5 Chiasson JL, Rabasa-Lhoret R. Prevention of type 2 diabetes: insulin resistance and beta-cell function.  Diabetes. 2004;  53 S34-S38
    PubMedGoogle Scholar
  • 6 Conget I, Fernandez Real JM, Costa A, Casamitjana R, Ricart W. Insulin secretion and insulin sensitivity in relation to glucose tolerance in a group of subjects at a high risk for type 2 diabetes mellitus.  Med Clin. 2001;  116 491-492
    PubMedGoogle Scholar
  • 7 Crepaldi G, Belfiore F, Bosello O, Caviezel F, Contaldo F, Enzi G, Melchionda N. Italian Consensus Conference; overweight, obesity and health (ICC S.O.S 1991).  Recenti Prog Med. 1991;  82 417-434
    PubMedGoogle Scholar
  • 8 DECODE Study Group. European Diabetes Epidemiology Group . Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?.  Diabetes Care. 2003;  26 688-696
    CrossrefPubMedGoogle Scholar
  • 9 DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake.  Metabolism. 1989;  38 387-395
    CrossrefPubMedGoogle Scholar
  • 10 Diamantopoulos EJ, Andreadis EA, Tsourous GI, Ifanti GK, Katsanou PM, Georgiopoulos DX, Vassilopoulos CV, Dimitriadis G, Raptis SA. Metabolic syndrome and prediabetes identify overlapping but not identical populations.  Exp Clin Endocrinol Diabetes. 2006;  114 377-383
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR).  J Clin Invest. 1997;  100 1166-1173
    CrossrefPubMedGoogle Scholar
  • 12 Ferrannini E, Camastra S, Gastaldelli A, Maria Sironi A, Natali A, Muscelli E, Mingrone G, Mari A. Beta-cell function in obesity: effects of weight loss.  Diabetes. 2004;  53 S26-S33
    PubMedGoogle Scholar
  • 13 Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Pettiti M, Natali A, Mari A, DeFronzo RA. Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance.  Diabetologia. 2003;  46 1211-1219
    CrossrefPubMedGoogle Scholar
  • 14 Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis.  J Clin Endocrinol Metab. 2005;  90 493-500
    PubMedGoogle Scholar
  • 15 Festa A, D’Agostino Jr R, Hanley AJ, Karter AJ, Saad MF, Haffner SM. Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose.  Diabetes. 2004;  53 1549-1555
    CrossrefPubMedGoogle Scholar
  • 16 Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P. Expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus.  Diabetes Care. 2003;  26 3160-3167
    CrossrefPubMedGoogle Scholar
  • 17 Guerrero-Romero F, Rodriguez-Moran M. Impaired glucose tolerance is a more advanced stage of alteration in the glucose metabolism than impaired fasting glucose.  J Diabetes Complications. 2001;  15 34-37
    CrossrefPubMedGoogle Scholar
  • 18 Gutt M, Davis CL, Spitzer SB, Llabre MM, Kumar M, Czarnecki EM, Schneiderman N, Skyler JS, Marks JB. Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures.  Diabetes Res Clin Pract. 2000;  47 177-184
    CrossrefPubMedGoogle Scholar
  • 19 Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H. A prospective analysis of the HOMA model. The mexico city diabetes study.  Diabetes Care. 1996;  19 1138-1141
    CrossrefPubMedGoogle Scholar
  • 20 Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?.  JAMA. 1990;  263 2893-2898
    CrossrefPubMedGoogle Scholar
  • 21 Hanefeld M, Koehler C, Henkel E, Fuecker K, Schaper F, Temelkova-Kurktschiev T. Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD study. Risk factors in impaired glucose tolerance for atherosclerosis and diabetes.  Diabet Med. 2000;  17 835-840
    CrossrefPubMedGoogle Scholar
  • 22 Hanefeld M, Temelkova-Kurktschiev T, Schaper F, Henkel E, Siegert G, Koehler C. Impaired fasting glucose is not a risk factor for atherosclerosis.  Diabet Med. 1999;  16 212-218
    CrossrefPubMedGoogle Scholar
  • 23 Letizia C, Iacobellis G, Caliumi C, Leonetti F, Cotesta D, Ribaudo MC, Petramala L, Cianci R, Celi M, D'Erasmo E, Mario U Di. Acute hyperinsulinemia is associated with increased plasma adrenomedullin concentrations in uncomplicated obesity.  Exp Clin Endocrinol Diabetes. 2005;  113 171-175
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
    Google Scholar
  • 25 Mittendorfer B. Insulin resistance: sex matters.  Curr Opin Clin Nutr Metab Care. 2005;  8 367-372
    CrossrefPubMedGoogle Scholar
  • 26 National Diabetes Data Group . Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.  Diabetes. 1979;  28 1039-1057
    PubMedGoogle Scholar
  • 27 Novoa FJ, Boronat M, Saavedra P, Diaz-Cremades JM, Varillas VF, La Roche F, Alberiche MP, Carrillo A. Differences in cardiovascular risk factors, insulin resistance, and insulin secretion in individuals with normal glucose tolerance and in subjects with impaired glucose regulation: the Telde Study.  Diabetes Care. 2005;  28 2388-2393
    CrossrefPubMedGoogle Scholar
  • 28 O’Rahilly S, Hattersley A, Vaag A, Gray H. Insulin resistance as the major cause of impaired glucose tolerance: a self-fulfilling prophesy?.  Lancet. 1994;  344 585-589
    CrossrefPubMedGoogle Scholar
  • 29 Piche ME, Despres JP, Pascot A, Nadeau A, Tremblay A, Weisnagel SJ, Bergeron J, Lemieux S. Impaired fasting glucose vs. glucose intolerance in pre-menopausal women: distinct metabolic entities and cardiovascular disease risk?.  Diabet Med. 2004;  21 730-737
    CrossrefPubMedGoogle Scholar
  • 30 Pimenta W, Korytkowski M, Mitrakou A, Jenssen T, Yki-Jarvinen H, Evron W, Dailey G, Gerich J. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative.  JAMA. 1995;  273 1855-1861
    CrossrefPubMedGoogle Scholar
  • 31 Staiger H, Haring HU. Adipocytokines: fat-derived humoral mediators of metabolic homeostasis.  Exp Clin Endocrinol Diabetes. 2005;  113 67-79
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, Haeften T Van, Renn W, Gerich J. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity.  Diabetes Care. 2000;  23 295-301
    CrossrefPubMedGoogle Scholar
  • 33 Stumvoll M, Haeften T Van, Fritsche A, Gerich J. Oral glucose tolerance test indexes for insulin sensitivity and secretion based on various availabilities of sampling times.  Diabetes Care. 2001;  24 796-797
    CrossrefPubMedGoogle Scholar
  • 34 Tai ES, Goh SY, Lee JJ, Wong MS, Heng D, Hughes K, Chew SK, Cutter J, Chew W, Gu K, Chia KS, Tan CE. Lowering the criterion for impaired fasting glucose: impact on disease prevalence and associated risk of diabetes and ischemic heart disease.  Diabetes Care. 2004;  27 1728-1734
    CrossrefPubMedGoogle Scholar
  • 35 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus . Report of the expert committee on the diagnosis and classification of diabetes mellitus.  Diabetes Care. 1997;  20 1183-1197
    PubMedGoogle Scholar
  • 36 Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen MR, Tuomi T, Groop LC. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study.  Diabetes. 2000;  49 975-980
    PubMedGoogle Scholar
  • 37 Tuomilehto J. Point: a glucose tolerance test is important for clinical practice.  Diabetes Care. 2002;  25 1880-1882
    PubMedGoogle Scholar
  • 38 Weyer C, Bogardus C, Pratley RE. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance.  Diabetes. 1999;  48 2197-2203
    PubMedGoogle Scholar

Correspondence

Prof. E. Bartoli

Internal Medicine

Dipartimento di Medicina Clinica e Sperimentale

Via Solaroli 17

28100 Novara

Italy

Phone: +39/0321/373 33 61

Fax: +39/0321/373 38 41

Email: bartoli@med.unipmn.it

      >